The Inflation Reduction Act (IRA): Are Community Oncology Practices Prepared?
The IRA brings sweeping changes, including new drug negotiation policies and Part D plan redesign. These reforms will have far-reaching effects on community oncology practices. One key impact? Lower drug prices resulting from Centers for Medicare & Medicaid Services (CMS) negotiations could reduce drug revenues—a crucial source of financial stability for many community oncology practices relying on buy-and-bill revenue. Our 2024 Community Oncology Report highlights the level of IRA awareness among community oncology practices as well as initial actions to address potential impacts.
IRA awareness is high in community oncology practices, but action lags:
The complexity and uncertainty surrounding the IRA's implementation are causing many community oncology practices to pause. They understand that action is necessary, but struggle with quantifying the precise impacts and developing flexible strategies to adapt.
Initial community practice responses remain limited to discussions among leadership including:
As IRA's implementation continues, it's crucial for community oncology practices to move from awareness to action.
Stay tuned for our upcoming 2024 Landscape Report Part 2, set to release in October, for an even deeper dive into the expected impact of the IRA on providers and the implications for manufacturers.
In the meantime, I'm here to answer your questions and would love to hear from you! Send me a note at ebijesse@hmplgobal.com.
Welcome to the August 2024 edition of our Monthly Insight Series! This month we are combining insights from 3 of our customer segment reports and reflecting on provider and payer relationships.
Emma BijesseThe ATOPP Summit covered a range of cutting-edge topics, including the shift toward administering cellular therapies to patients in community oncology settings.
Emma Bijesse, Daniel BuchenbergerWelcome to our Monthly Insight Series July 2024 edition! This month we discuss our 2024 research regarding the ever-rising integration across vertical payers’ health plans, PBMs, and SPs, including around manufacturer contracting.
Chris Van Denburg